Manufacturing Issue Results in "Complete Response" Letter For Warner Chilcott Contraceptive
This article was originally published in The Pink Sheet Daily
Executive Summary
Warner Chilcott hopes to receive FDA approval for the low-dose product within six months.
You may also be interested in...
Actonel Delayed-Release Back On Track With New PDUFA Date In October
Three-month extension clarifies regulatory outlook for Warner Chilcott's once-weekly successor to osteoporosis blockbuster Actonel.
Actonel Delayed-Release Back On Track With New PDUFA Date In October
Three-month extension clarifies regulatory outlook for Warner Chilcott's once-weekly successor to osteoporosis blockbuster Actonel.
Warner Chilcott Transformation Underway With Integration Of P&G's Pharma Biz
With the acquisition of Procter & Gamble's pharma business complete, the specialty drug maker adds 1,900 employees.